Azercabtagene zapreleucel
| CAS No. | AZ | Cat. No. | BCP49519 |
| Name | Azercabtagene zapreleucel | ||
| Synonyms | PBCAR 0191; | ||
| Formula | M. Wt | ||
| Description | Azercabtagene Zapreleucel is a preparation of allogeneic, off-the-shelf, T-lymphocytes that have been genetically modified using a proprietary synthetic nuclease-based system to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 (cluster of differentiation 19) with potential immunostimulating and antineoplastic activities. Upon administration, azercabtagene zapreleucel specifically recognize and kill CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen, which is expressed in all B-cell lineage malignancies and normal B-cells. | ||
| Pathways | Others Pathway | ||
| Targets | Others | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.